In the 58-patient randomized, double-blind, placebo-controlled clinical trial, conducted at two study centers in the US, the group consisting of 30 subjects who received ALGRX 4975 (100 micrograms) by a single injection into the neuroma had statistically significant decreases in their foot pain four weeks after the single administration of study drug.
Additionally, ALGRX 4975 was well tolerated and did not demonstrate any significant safety issues.
“The strong pain relief demonstrated in this phase II trial of ALGRX 4975 contributes to the growing body of data which demonstrate that this product candidate may be a safe and effective drug for a variety of moderate to severe pain syndromes,” stated Dr Ronald Burch, CEO of AlgoRx.